Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT.
Although the feasibility of using HLA-mismatched unrelated donors as an alternate graft source for haematopoietic SCT (HSCT) has been shown, little is known about the safety of HLA-mismatched DLI for the treatment of relapse. We examined the outcome of 58 consecutive leukaemia patients who received...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Nature Publishing Group
2013
|
| _version_ | 1826266329012764672 |
|---|---|
| author | Innes, A Beattie, R Sergeant, R Damaj, D Foroni, L Marin, D Kanfer, E Mielke, S Milojkovic, D MacDonald, D Pavlu, J Rahemtulla, A Roberts, I Slade, D Bray, E Goldman, J Apperley, J Szydlo, R Dazzi, F Rezvani, K |
| author_facet | Innes, A Beattie, R Sergeant, R Damaj, D Foroni, L Marin, D Kanfer, E Mielke, S Milojkovic, D MacDonald, D Pavlu, J Rahemtulla, A Roberts, I Slade, D Bray, E Goldman, J Apperley, J Szydlo, R Dazzi, F Rezvani, K |
| author_sort | Innes, A |
| collection | OXFORD |
| description | Although the feasibility of using HLA-mismatched unrelated donors as an alternate graft source for haematopoietic SCT (HSCT) has been shown, little is known about the safety of HLA-mismatched DLI for the treatment of relapse. We examined the outcome of 58 consecutive leukaemia patients who received escalating-dose DLI for treatment of relapse after alemtuzumab-conditioned myeloablative unrelated donor HSCT at our institution. High-resolution HLA typing on stored DNA samples revealed mismatches in 28/58 patients who were considered HLA-matched at the time of transplantation. Following DLI from HLA-matched (10/10) (n=30) or -mismatched (7-9/10) (n=28) unrelated donors, we found no significant difference in the incidence of acute GVHD (17.2% versus 23.1%, P=0.59), probability of remission at 3 years (62.1% versus 63.9%, P=0.89) or 5-year OS (89.8% versus 77.7%, P=0.22). We conclude that escalating-dose DLI can be safely given to HLA-mismatched recipients following T-depleted myeloablative HSCT. |
| first_indexed | 2024-03-06T20:37:14Z |
| format | Journal article |
| id | oxford-uuid:330b7896-d9ff-43cc-af32-d236d9c964a0 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:37:14Z |
| publishDate | 2013 |
| publisher | Nature Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:330b7896-d9ff-43cc-af32-d236d9c964a02022-03-26T13:18:02ZEscalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:330b7896-d9ff-43cc-af32-d236d9c964a0EnglishSymplectic Elements at OxfordNature Publishing Group2013Innes, ABeattie, RSergeant, RDamaj, DForoni, LMarin, DKanfer, EMielke, SMilojkovic, DMacDonald, DPavlu, JRahemtulla, ARoberts, ISlade, DBray, EGoldman, JApperley, JSzydlo, RDazzi, FRezvani, KAlthough the feasibility of using HLA-mismatched unrelated donors as an alternate graft source for haematopoietic SCT (HSCT) has been shown, little is known about the safety of HLA-mismatched DLI for the treatment of relapse. We examined the outcome of 58 consecutive leukaemia patients who received escalating-dose DLI for treatment of relapse after alemtuzumab-conditioned myeloablative unrelated donor HSCT at our institution. High-resolution HLA typing on stored DNA samples revealed mismatches in 28/58 patients who were considered HLA-matched at the time of transplantation. Following DLI from HLA-matched (10/10) (n=30) or -mismatched (7-9/10) (n=28) unrelated donors, we found no significant difference in the incidence of acute GVHD (17.2% versus 23.1%, P=0.59), probability of remission at 3 years (62.1% versus 63.9%, P=0.89) or 5-year OS (89.8% versus 77.7%, P=0.22). We conclude that escalating-dose DLI can be safely given to HLA-mismatched recipients following T-depleted myeloablative HSCT. |
| spellingShingle | Innes, A Beattie, R Sergeant, R Damaj, D Foroni, L Marin, D Kanfer, E Mielke, S Milojkovic, D MacDonald, D Pavlu, J Rahemtulla, A Roberts, I Slade, D Bray, E Goldman, J Apperley, J Szydlo, R Dazzi, F Rezvani, K Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT. |
| title | Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT. |
| title_full | Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT. |
| title_fullStr | Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT. |
| title_full_unstemmed | Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT. |
| title_short | Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT. |
| title_sort | escalating dose hla mismatched dli is safe for the treatment of leukaemia relapse following alemtuzumab based myeloablative allo sct |
| work_keys_str_mv | AT innesa escalatingdosehlamismatcheddliissafeforthetreatmentofleukaemiarelapsefollowingalemtuzumabbasedmyeloablativeallosct AT beattier escalatingdosehlamismatcheddliissafeforthetreatmentofleukaemiarelapsefollowingalemtuzumabbasedmyeloablativeallosct AT sergeantr escalatingdosehlamismatcheddliissafeforthetreatmentofleukaemiarelapsefollowingalemtuzumabbasedmyeloablativeallosct AT damajd escalatingdosehlamismatcheddliissafeforthetreatmentofleukaemiarelapsefollowingalemtuzumabbasedmyeloablativeallosct AT foronil escalatingdosehlamismatcheddliissafeforthetreatmentofleukaemiarelapsefollowingalemtuzumabbasedmyeloablativeallosct AT marind escalatingdosehlamismatcheddliissafeforthetreatmentofleukaemiarelapsefollowingalemtuzumabbasedmyeloablativeallosct AT kanfere escalatingdosehlamismatcheddliissafeforthetreatmentofleukaemiarelapsefollowingalemtuzumabbasedmyeloablativeallosct AT mielkes escalatingdosehlamismatcheddliissafeforthetreatmentofleukaemiarelapsefollowingalemtuzumabbasedmyeloablativeallosct AT milojkovicd escalatingdosehlamismatcheddliissafeforthetreatmentofleukaemiarelapsefollowingalemtuzumabbasedmyeloablativeallosct AT macdonaldd escalatingdosehlamismatcheddliissafeforthetreatmentofleukaemiarelapsefollowingalemtuzumabbasedmyeloablativeallosct AT pavluj escalatingdosehlamismatcheddliissafeforthetreatmentofleukaemiarelapsefollowingalemtuzumabbasedmyeloablativeallosct AT rahemtullaa escalatingdosehlamismatcheddliissafeforthetreatmentofleukaemiarelapsefollowingalemtuzumabbasedmyeloablativeallosct AT robertsi escalatingdosehlamismatcheddliissafeforthetreatmentofleukaemiarelapsefollowingalemtuzumabbasedmyeloablativeallosct AT sladed escalatingdosehlamismatcheddliissafeforthetreatmentofleukaemiarelapsefollowingalemtuzumabbasedmyeloablativeallosct AT braye escalatingdosehlamismatcheddliissafeforthetreatmentofleukaemiarelapsefollowingalemtuzumabbasedmyeloablativeallosct AT goldmanj escalatingdosehlamismatcheddliissafeforthetreatmentofleukaemiarelapsefollowingalemtuzumabbasedmyeloablativeallosct AT apperleyj escalatingdosehlamismatcheddliissafeforthetreatmentofleukaemiarelapsefollowingalemtuzumabbasedmyeloablativeallosct AT szydlor escalatingdosehlamismatcheddliissafeforthetreatmentofleukaemiarelapsefollowingalemtuzumabbasedmyeloablativeallosct AT dazzif escalatingdosehlamismatcheddliissafeforthetreatmentofleukaemiarelapsefollowingalemtuzumabbasedmyeloablativeallosct AT rezvanik escalatingdosehlamismatcheddliissafeforthetreatmentofleukaemiarelapsefollowingalemtuzumabbasedmyeloablativeallosct |